Lindsay Androski
Net worth: 19 876 $ as of 2026-06-29
Net worth: 19 876 $ as of 2026-06-29
Lindsay Androski is currently President, Chief Executive Officer & Director at Roivant Social Ventures, Inc. since 2020, Chairman, President & Chief Executive Officer at Arbutus Biopharma Corp.
starting in 2025, President & Director at Incubate Coalition, Trustee at Massachusetts Institute of Technology, and Special Counsel at Genevant Sciences Corp.
since 2023.
Former roles include Independent Director at Eloxx Pharmaceuticals, Inc. from 2022 to 2025.
Education includes undergraduate studies at Massachusetts Institute of Technology and graduate studies including an MBA at The University of Chicago Booth School of Business.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-01-23 | 1,432 ( 0.31% ) | 19 876 $ | 2026-06-29 | |
| 2026-03-29 | 0 ( -.--% ) | - $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Chief Executive Officer | 2025-02-23 |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Director/Board Member | - |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | Chief Executive Officer | 2020-06-30 |
Incubate Coalition
Incubate Coalition Investment ManagersFinance Provides venture capital investment services for life sciences | President | - |
Genevant Sciences Corp.
Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 2023-04-30 |
| Companies | Position | End |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Director/Board Member | 2025-08-05 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The University of Chicago Booth School of Business
The University of Chicago Booth School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that discovers and develops therapeutics to treat cystic fibrosis, inherited retinal disorders and other diseases | Health Technology |
Genevant Sciences Corp.
Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | |
Incubate Coalition
Incubate Coalition Investment ManagersFinance Provides venture capital investment services for life sciences | Finance |
Select your edition
All financial news and data tailored to specific country editions